CNC · Centene Corporation

The thesis

Centene's shares closed at $68.03 on 26 October 2026, 4.5% below the $71.24 52-week high, on the day it reports third-quarter 2026 results. The report decides whether fiscal 2026 adjusted earnings per share (EPS) guidance of more than $4.80 holds. After a 10.0% three-month gain, the shares price in a guidance-held quarter, so an in-line print leaves little upside.

Centene last reaffirmed guidance on 16 September 2026 (Form 8-K). The Q3 release and call run 8:30–9:30 a.m. EDT on 27 October 2026, and results were not yet public when this note was written. The 14-day relative strength index (RSI) has cooled from 80.1 on 13 October 2026 to 60.9 on 26 October 2026.

The narrative is maturing: the margin-repair story has been public since the first-quarter guidance raise, and StockStory put the year-to-date gain at 64.9% as of 13 October 2026. Since the previous note, peer Molina reported an in-line Medicaid quarter on 21 October 2026 and Centene announced its exit from Hawaii's Medicaid program. The rating stays where it was, because neither fact changes what the 27 October 2026 report has to show.

Bullish and bearish views on Centene Corporation

The bull case on Centene Corporation (CNC), in brief: Guidance held late in the year. The bear case: Medicare star ratings fell for 2027.

Bull case

• Guidance held late in the year. On 16 September 2026 Centene reaffirmed fiscal 2026 adjusted diluted EPS of more than $4.80 and GAAP EPS of more than $3.11. Analyst estimates for FY2026 adjusted EPS ranged from $4.80 to $5.09 around a $4.89 average across 20 analysts as of 16 August 2026, per Benzinga.
• Peer Medicaid margins held. Molina reported a Q3 Medicaid medical care ratio of 93.0%, in line with its expectations, and adjusted EPS of $0.89 against a $0.79 estimate on 21 October 2026. Its CEO said medical cost trend appears to be plateauing, per 247WallSt coverage.
• Second-quarter margins were reported results. The 28 July 2026 release showed adjusted EPS of $2.51 and a consolidated health benefits ratio (HBR, medical costs as a share of premium revenue) of 89.6% (Q2 results).
• Contract discipline and early debt retirement. An 8-K filed 8 October 2026 set the redemption of all $568,664,000 of 4.25% notes due 15 December 2027 for 23 October 2026, leaving no 2027 notes outstanding. Centene is also leaving Hawaii's Med-QUEST program on 31 December 2026, citing rates that have not kept pace with costs (Honolulu Star-Advertiser, 18 October 2026).
• One sell-side target sits above the price. Cantor Fitzgerald raised its target from $60 to $75 and kept Overweight on 7 July 2026.

Bear case

• Medicare star ratings fell for 2027. Fierce Healthcare reported on 8 October 2026 that 9% of Centene's Medicare Advantage members are in plans rated four stars or higher for 2027, down from 18% for 2026. The lower ratings weigh on 2028 quality bonus payments (Fierce Healthcare).
• Medicaid remains the cost-pressure segment. The Q2 Medicaid HBR was 93.9% (28 July 2026 release). Molina's Medicaid ratio of 93.0% was higher than the 92.0% a year earlier, and its net income fell 52% to $38 million, per 247WallSt.
• Part of the guidance raise was one-off. The 28 July 2026 release attributed about $0.50 per share to largely nonrecurring 2025 Marketplace and Medicare settlements.
• Marketplace enrollment faces a federal clean-up. On 22 September 2026 Benzinga relayed a Wall Street Journal report that a Vance-led task force is set to remove about 760,000 allegedly fraudulent ACA enrollments.
• Membership is shrinking at peers and at Centene in Hawaii. Molina's Q3 premium revenue fell about 4% to $10.5 billion on lower Medicaid and Marketplace membership. Centene's Hawaii exit removes roughly 24,000 members on 31 December 2026.

Price setup

The adjusted daily close was $68.03 on 26 October 2026, against a 52-week high of $71.24. The shares closed at $62.12 on 30 September 2026 and $68.86 on 13 October 2026, so the October rebound has held most of its gain into the report. The $62 invalidation level from the previous note sits 8.9% below the 26 October 2026 close.

Crowding evidence is visible in two places. The earnings date is the day of this note, and the year-to-date gain was 64.9% as of 13 October 2026 per StockStory. The 52-week high rose from $69.41 to $71.24 between 13 October 2026 and 26 October 2026, so buyers paid higher prices into the report. No insider-selling or share-issuance filings were found for this note.

Catalysts, next 30 days

• November 2026 — Gold Card launch. Centene's national performance-based prior-authorization program covers more than 160,000 qualifying providers; the exact date has not been announced.
• 31 December 2026 — Hawaii exit (outside the 30 days). The 'Ohana Health Plan leaves Med-QUEST; the Q3 call may size the revenue effect.

Elapsed catalysts

• 27 October 2026 — Q3 results and call (8:30–9:30 a.m. EDT). Shows whether guidance of more than $4.80 is renewed, raised or cut, and whether the Medicaid HBR moved from 93.9%. (passed 10d ago)

What would change the view

The operating case breaks if Centene cuts or withdraws fiscal 2026 adjusted EPS guidance of more than $4.80 on 27 October 2026, or if the Medicaid HBR rises above Q2's 93.9% and management attributes it to cost trend rather than timing. A quantified star-ratings headwind for 2028 would also weaken it.

On price, a daily close below $62 would erase the October rebound from the $62.12 close on 30 September 2026. Reaffirmed or raised guidance with a Medicaid HBR at or below 93.9% would strengthen the margin-repair reading and make a higher rating more likely.

What it trades with

Centene moves with the managed-care group, and Molina's 21 October 2026 report is the closest peer read on Medicaid cost trend. Policy news on ACA marketplace enrollment and CMS rulemaking can move the shares independently of quarterly results. The 10-year Treasury yield hit a 19-month high in early September (Benzzinga, 1 September 2026), which pressured high-multiple software more than managed care, so rates are a secondary influence on this name.